tolbutamide has been researched along with flurbiprofen in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Anacardio, R; Aureli, L; Cesta, MC; Cruciani, G; De Simone, L; Moriconi, A | 1 |
| Carrupt, PA; Martel, S; Ottaviani, G | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Feron, VJ; Groene, EM; Horbach, GJ; Kappers, WA; Kleij, LA; Witkamp, RF; Zweers-Zeilmaker, WM | 1 |
| Blaisdell, JA; Frye, RF; Goldstein, JA; Hinderliter, AL; Lee, CR; Pieper, JA | 1 |
| Gorman, LA; Kumar, V; Rock, DA; Tracy, TS; Wahlstrom, JL; Warren, CJ | 1 |
| Agrawal, V; Miller, WL; Sandee, D; Subramanian, M; Tam, HK; Tracy, TS | 1 |
| Srinivas, NR | 1 |
| Inoue, T; Kawano, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Glatz, Z; Michalcová, L; Nevídalová, H | 1 |
1 review(s) available for tolbutamide and flurbiprofen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for tolbutamide and flurbiprofen
| Article | Year |
|---|---|
Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C9; Female; Flurbiprofen; Genotype; Humans; Losartan; Male; Phenotype; Tolbutamide | 2003 |
20 other study(ies) available for tolbutamide and flurbiprofen
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Chemical Phenomena; Chemistry, Physical; Humans; In Vitro Techniques; Interleukin-8; Models, Molecular; Phenylpropionates; Protein Binding; Quantitative Structure-Activity Relationship; Serum Albumin; Stereoisomerism | 2005 |
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
Topics: Humans; Membranes, Artificial; Models, Biological; Models, Molecular; Octanols; Permeability; Pharmaceutical Preparations; Skin Absorption; Water | 2007 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Inhibition of tolbutamide 4-methylhydroxylation by a series of non-steroidal anti-inflammatory drugs in V79-NH cells expressing human cytochrome P4502C10.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Cell Line; Cricetinae; Cricetulus; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Diclofenac; Drug Interactions; Enzyme Inhibitors; Flurbiprofen; Gene Expression; Humans; Hydroxylation; Ketoprofen; Lung; Methylation; Mixed Function Oxygenases; Phenylbutazone; Sulfaphenazole; Tolbutamide; Transfection | 1996 |
CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diclofenac; Enzyme Inhibitors; Flurbiprofen; Genotype; In Vitro Techniques; Pharmacogenetics; Phenytoin; Piroxicam; Tolbutamide; Warfarin | 2006 |
Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3.
Topics: Aryl Hydrocarbon Hydroxylases; Catalysis; Cytochrome P-450 CYP2C9; Diclofenac; Flurbiprofen; Humans; Kinetics; NADPH-Ferrihemoprotein Reductase; Polymorphism, Genetic; Recombinant Proteins; Tolbutamide | 2012 |
Is pomegranate juice a potential perpetrator of clinical drug-drug interactions? Review of the in vitro, preclinical and clinical evidence.
Topics: Animals; Anti-Anxiety Agents; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Beverages; Buspirone; Caco-2 Cells; Calcium Channel Blockers; Carbamazepine; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Evaluation, Preclinical; Drug Interactions; Flurbiprofen; Food-Drug Interactions; Humans; Hypnotics and Sedatives; Hypoglycemic Agents; Lythraceae; Midazolam; Nitrendipine; Tolbutamide; Triazolam | 2013 |
Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole.
Topics: Amino Acid Sequence; Animals; Callithrix; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Female; Flurbiprofen; Humans; Macaca fascicularis; Male; Microsomes, Liver; Molecular Sequence Data; Omeprazole; Phylogeny; Species Specificity; Substrate Specificity; Tolbutamide; Warfarin | 2015 |
Applicability of capillary electrophoresis-frontal analysis for displacement studies: Effect of several drugs on l-tryptophan and lidocaine binding to human serum albumin.
Topics: Binding Sites; Chlorpropamide; Diclofenac; Electrophoresis, Capillary; Flurbiprofen; Humans; Ibuprofen; Lidocaine; Phenylbutazone; Serum Albumin, Human; Tolbutamide; Tryptophan | 2020 |